It was reported on Tuesday, that DxTerity Diagnostics Inc, a molecular information and diagnostics company, has named Brett Swansiger as its new chief commercialization officer (CCO).
Swansiger will be responsible for identifying, developing, and negotiating strategic business collaborations with life-science organizations and establishing government and commercial payer contracts for DxTerity testing. Swansiger has experience managing care contracting in the molecular diagnostics and pharmaceutical industries. Prior to joining DxTerity, he held commercial leadership positions at MDxHealth Inc including VP of Managed Care and Payer Strategy, SVP International Business Development & European Sales, and SVP of US Sales & Integrated Healthcare Systems.
Swasniger was earlier vice president of Managed Care and Asia Market Access at Agendia Inc and held a number of commercial leadership roles at Prometheus Laboratories Inc.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business